{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009383","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.663438+00:00","generated_at":"2026-06-15T03:49:55.981168+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aytu BioPharma Q3 revenue $22.7M (-6% YoY); net loss narrows to $7.2M","bullets":["Total net revenue $22.7M, down 6% from $24.2M; net loss ($7.2M) vs ($53.3M) last year.","Record total prescriptions 153,452 (+32% YoY); ADHD prescriptions up 27%.","Rx segment revenue $13.8M; ADHD revenue down 21% to $8.3M due to $1.2M channel inventory adjustment.","Pediatric products revenue up 81% to $5.3M; Consumer Health down 14% to $8.9M.","Gross margin improved to 56% from 52%; cash $19.2M; FDA approval for Adzenys manufacturing transfer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009383","json":"https://secwatch.observer/filing/0001558370-23-009383.json","markdown":"https://secwatch.observer/filing/0001558370-23-009383.md","text":"https://secwatch.observer/filing/0001558370-23-009383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023009383/0001558370-23-009383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023009383/aytu-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:49:55.981168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40003af1102d7158fa62d037f04124d10b7c2ac1","claim":"AYTU BIOPHARMA, INC reported the quarter ended March 31, 2023 results: revenue $22.7 million, net income $(7.2) million, EPS ($1.93) per share.","evidence_excerpt":"Q3 2023 Commercial Highlights (3 months ending March 31, 2023) ● Total net revenue was $22.7 million, a decrease of 6% from the $24.2 million in net revenue in the year-ago quarter. Revenue during Q3 2023 was impacted by a one-time $1.2 million channel inventory adjustment due to an ADHD products price increase instituted on April 1, 2023. Excluding this impact, net revenue would have been $23.9 million, in-line with the year-ago quarter. ● Record total quarterly prescriptions of 153,452, a 32% increase over Q3 2022. ● Net revenue from the Company’s Rx segment was $13.8 million during Q3 2023 compared to $13.9 million in the year-ago quarter. o ADHD products (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue decreased by 21% to $8.3 million from $10.4 million in the year ago quarter. o Pediatric products (Poly-Vi-Flor®, Tri-Vi-Flor®, and Karbinal® ER) net revenue increased 81% to $5.3 million, from $2.9 million in the year-ago quarter. ● Consumer Health revenue during Q3 2023 was $8.9","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023009383/0001558370-23-009383-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$22.7 million"},{"label":"Net income","value":"$(7.2) million"},{"label":"EPS","value":"($1.93) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}